Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "25" vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydrochlorothiazide is not extensively metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Reserpine: 95-98% bound to plasma proteins; hydrochlorothiazide: 60-70% bound to albumin.
~20% bound to albumin; minimal binding to other plasma proteins.
Reserpine: Vd approximately 0.5-0.7 L/kg, indicating extensive tissue distribution and high lipophilicity; hydrochlorothiazide: Vd 0.2-0.4 L/kg, primarily confined to extracellular fluid.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Reserpine: oral bioavailability approximately 50% due to first-pass metabolism; hydrochlorothiazide: oral bioavailability 65-75%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-50 m L/min: 25 mg once daily. GFR 15-29 m L/min: not recommended. GFR <15 m L/min: contraindicated.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh Class A or B: no adjustment. Child-Pugh Class C: use with caution, consider starting at 12.5 mg daily.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Weight-based: 1-2 mg/kg/day orally divided every 12-24 hours, maximum 100 mg/day.
Not recommended; inadequate safety data.
Start at 12.5 mg daily; monitor electrolytes and renal function; may increase to 25 mg daily if needed.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
May cause electrolyte imbalance (hypokalemia, hyponatremia),May exacerbate systemic lupus erythematosus,Reserpine may cause mental depression, peptic ulcer, and nasal congestion,Photosensitivity,Orthostatic hypotension with reserpine
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Anuria,Sulfonamide allergy (hydrochlorothiazide is a sulfonamide),Known hypersensitivity to hydrochlorothiazide or reserpine,Active peptic ulcer (due to reserpine),Electroconvulsive therapy (within 7 days, due to reserpine)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-sodium foods to enhance antihypertensive effect. Limit alcohol intake as it may potentiate hypotension. Grapefruit juice may alter drug metabolism; avoid excessive consumption. Maintain adequate potassium intake (bananas, oranges) unless advised otherwise by your doctor.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. In the second and third trimesters, exposure may cause fetal bradycardia, hypothermia, and respiratory depression due to depletion of catecholamines. Chronic use may lead to fetal growth restriction.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine is excreted into breast milk with an M/P ratio of 0.5. Due to the potential for serious adverse reactions in nursing infants, including gastrointestinal disturbances, nasal congestion, and lethargy, breastfeeding is contraindicated during reserpine therapy.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No pharmacokinetic studies are available to guide dosing adjustments during pregnancy; however, due to increased plasma volume and renal clearance, the effective dose may need to be increased, but this must be balanced against fetal risks. The lowest effective dose should be used and the drug should be discontinued if possible, especially during the third trimester to avoid neonatal effects.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Hydro-Serp '25' contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause mental depression; use with caution in patients with history of depression. Taper reserpine before surgery to avoid hypertensive rebound. Avoid concurrent use with MAOIs.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed; do not discontinue abruptly.,This medication may make you dizzy or drowsy; avoid driving until you know how it affects you.,Rise slowly from sitting or lying to prevent falls from low blood pressure.,Report any mood changes, depression, or vivid dreams to your doctor.,Use sunscreen and protective clothing; this drug increases sun sensitivity.,Do not use potassium supplements or salt substitutes without asking your doctor.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "25" vs ALDORIL D50, answered by our medical review team.
HYDRO-SERP "25" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "25" and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "25" is: Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "25" and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "25" is classified as Category C. FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.